Result of EGM
09 Februar 2009 - 1:39PM
UK Regulatory
TIDMAVCT TIDMCUR
RNS Number : 0135N
Avacta Group PLC
09 February 2009
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION
London, 9 February 2009
Avacta Group plc ("Avacta")
Offer Update: Result of Shareholder Meeting
The Avacta Board is pleased to announce that, at the Avacta General Meeting held
earlier today in relation to
the recommended offer for Curidium Medica plc ("Curidium") by Avacta (the
"Proposed Acquisition"), the Avacta Resolutions necessary to effect the Proposed
Acquisition were passed by the requisite majorities.
The number of proxy votes lodged for each resolution before the meeting was as
follows:
+----------------------+-------------+---------+---------+---------+------------+
| | Total For* | Total Against | Votes |
| | | | Withheld |
+----------------------+-----------------------+-------------------+------------+
| Resolution | No. of | %age of | No. of | %age of | No. of |
| | votes | vote | votes | vote | votes |
+----------------------+-------------+---------+---------+---------+------------+
| 1. To allot equity | 297,483,904 | 98.6 | 60,000 | 0.02 | 0 |
| securities in | | | | | |
| connection with the | | | | | |
| Scheme | | | | | |
+----------------------+-------------+---------+---------+---------+------------+
| 2. To adopt the EMI | 297,543,904 | 98.6 | 0 | 0 | 0 |
| Scheme | | | | | |
+----------------------+-------------+---------+---------+---------+------------+
*Figures do not include discretionary votes.
Implementation of the Scheme of Arrangement remains conditional upon the
approval by Curidium Scheme Shareholders of the resolutions at the Curidium
General Meeting and of the Scheme of Arrangement at the Court Meeting, both of
which are due to be held on 11 February 2009, and the satisfaction or (where
applicable) waiver of the other Conditions set out in the Scheme Document posted
to Curidium Shareholders on 16 January 2009.
On the basis that the Curidium resolutions are passed and that the Court
sanctions the Scheme of Arrangement and confirms the associated Reduction of
Capital at the Court Hearing scheduled to take place on 2 March 2009, it is
anticipated that, on 3 March 2009 the Scheme will become effective and that
dealings in the New Avacta Shares will commence on 4 March 2009. New Avacta
Shares will be credited to CREST accounts on the same date. It is expected that
share certificates for New Avacta Shares will be dispatched by no later than 17
March 2009.
Copies of the Avacta Resolutions passed at the Avacta General Meeting will be
available for inspection by the public from tomorrow at the offices of Avacta at
York Biocentre, York Science Park, Innovation Way, Heslington, York YO10 5NY and
also those of Walker Morris situated at: Kings Court, 12 Kings Street, Leeds LS1
2HL during normal business hours on any weekday (public holidays excepted) until
4 March 2009.
Terms used but not defined in this announcement shall have the same meaning as
in the Scheme Document dated 16 January 2009.
Enquiries
Avacta
Dr Alastair Smith, Chief Executive Officer
Tim Sykes, Chief Financial Officer
Tel: 0870 835 4367
Curidium
Dr. Barry Porter, Chairman
Rob Smith, Chief Financial Officer
Tel: 020 7554 5100
Novum Securities Limited (financial adviser to Avacta)
Henry Turcan
Tel: 020 7562 4700
FinnCap (financial adviser to Curidium)
Charlie Cunningham
Tel: 020 7600 1658
Haggie Financial (PR to Avacta)
Nicholas Nelson
Tel: 020 7417 8989
Novum Securities Limited, which is authorised and regulated in the UK by the
Financial Services Authority, is acting as financial adviser to Avacta in
connection with the Recommended Offer and no-one else and will not be
responsible to anyone other than Avacta for providing the protections afforded
to clients of Novum Securities nor for providing advice in relation to the
Recommended Offer nor any other matter referred to in this announcement.
FinnCap, which is authorised and regulated in the UK by the Financial Services
Authority, is acting as financial adviser and broker to Curidium in connection
with the Recommended Offer and no-one else and will not be responsible to anyone
other than Curidium for providing the protections afforded to clients of FinnCap
nor for providing advice in relation to the Recommended Offer nor any other
matter referred to in this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REGEAAANEDPNEFE
Curidium Medica (LSE:CUR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Curidium Medica (LSE:CUR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Curidium Medica (Londoner Börse): 0 Nachrichtenartikel
Weitere Curidium Medica News-Artikel